{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:28:06Z","timestamp":1790962086702,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T00:00:00Z","timestamp":1555891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijcha.2019.100367","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T02:19:17Z","timestamp":1557368357000},"page":"100367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany \u2014 A retrospective cohort study"],"prefix":"10.1016","volume":"23","author":[{"given":"Hendrik","family":"Bonnemeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Huelsebeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2019.100367_bb0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2019.100367_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2019.100367_bb0015","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.amjmed.2017.04.015","article-title":"Renal function considerations for stroke prevention in atrial fibrillation","volume":"130","author":"Fanikos","year":"2017","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcha.2019.100367_bb0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcha.2019.100367_bb0025","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2019.100367_bb0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcha.2019.100367_bb0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/cer.15.44","article-title":"Atrial fibrillation and chronic kidney disease: focus on rivaroxaban","volume":"4","author":"Barrios","year":"2015","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.ijcha.2019.100367_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2019.100367_bb0045","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2019.100367_bb0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.disamonth.2016.03.003","article-title":"Cancer-associated thrombosis","volume":"62","author":"Fuentes","year":"2016","journal-title":"Dis. Mon."},{"key":"10.1016\/j.ijcha.2019.100367_bb0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijcha.2019.100367_bb0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1160\/TH17-10-0733","article-title":"Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation","volume":"118","author":"Hohnloser","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcha.2019.100367_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/POR.S156521","article-title":"Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset","volume":"9","author":"Mueller","year":"2018","journal-title":"Pragmat. Obs. Res."},{"key":"10.1016\/j.ijcha.2019.100367_bb0070","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00228-018-2504-7","article-title":"Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation","volume":"74","author":"Ujeyl","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcha.2019.100367_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx504.P3581","article-title":"Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in Germany-insights from the RELOAD study","volume":"38","author":"Bonnemeier","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2019.100367_bb0080","doi-asserted-by":"crossref","unstructured":"T.I. Verhoef, W.K. Redekop, A.K. Daly, et al., Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon, Br. J. Clin. Pharmacol. 77 (2013) 626\u2013641.","DOI":"10.1111\/bcp.12220"},{"key":"10.1016\/j.ijcha.2019.100367_bb0085","unstructured":"Marcoumar\u00ae (Phenprocoumon) Prescribing Information. MEDA Pharmaceuticals, 2000 (accessed 27 September 2018)."},{"key":"10.1016\/j.ijcha.2019.100367_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12874-015-0013-2","article-title":"Positive predictive value of International Classification of Diseases, 10th revision, diagnosis codes for cardiogenic, hypovolemic, and septic shock in the Danish National Patient Registry","volume":"15","author":"Lauridsen","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ijcha.2019.100367_bb0095","series-title":"Xarelto\u00ae (Rivaroxaban) Summary of Product Characteristics","year":"2018"},{"key":"10.1016\/j.ijcha.2019.100367_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014579","article-title":"Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry","volume":"7","author":"Camm","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijcha.2019.100367_bb0105","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","article-title":"Causes of death and influencing factors in patients with atrial fibrillation","volume":"129","author":"Fauchier","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcha.2019.100367_bb0110","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2019.100367_bb0115","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2019.100367_bb0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2019.100367_bb0125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiol."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906718301702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906718301702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T22:24:17Z","timestamp":1573683857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906718301702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":25,"alternative-id":["S2352906718301702"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2019.100367","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany \u2014 A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2019.100367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100367"}}